肺癌是美国最常见的恶性肿瘤死亡原因，也是全球第二常见的癌症诊断。在过去二十年中，肺癌治疗已经发展到包括基于突变的靶向治疗、免疫治疗、放疗和微创手术技术的进步。肺癌作为一种分子异质性疾病的发现推动了对靶向治疗的研究，改善了患者预后。尽管取得了这些进展，但还存在机会通过进一步研究耐药机制来开发更好地个体化指导肺癌治疗的新疗法。在本综述中，我们重点介绍非小细胞肺癌靶向疗法发展的进展，以及受新兴耐药模式影响的未来方向。版权所有：© 2023 McLaughlin J等。

Lung cancer is the leading cause of malignancy-related death in the United States and the second most common cancer diagnosis worldwide. In the last two decades, lung cancer treatment has evolved to include advances in the development of mutation-based targeting, immunotherapy, radiation therapy, and minimally invasive surgical techniques. The discovery of lung cancer as a molecularly heterogeneous disease has driven investigation into the development of targeted therapies resulting in improved patient outcomes. Despite these advances, there remain opportunities, through further investigation of mechanisms of resistance, to develop novel therapeutics that better direct the personalization of lung cancer therapy. In this review, we highlight developments in the evolution of targeted therapies in non-small cell lung cancer, as well as future directions shaped by emerging patterns of resistance.Copyright: © 2023 McLaughlin J et al.